Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial

Hirotoshi Watanabe(Kyoto University), Takeshi Kimura(Kyoto University), Yuki Obayashi(Kyoto University), Kazuya Kawai(Chikamori Hospital), Ryusuke Nishikawa(Obayashi (Japan)), Kiyoshi Hibi(Yokohama City University Medical Center), Tsuyoshi Isawa(Sendai Kousei Hospital), Hiroshi Suzuki(Showa University Fujigaoka Hospital), Kohei Wakabayashi(SHOWA Medical University), Y Onishi(Hiratsuka Kyosai Hospital), Takanori Kusuyama(Yazaki (United States)), Itsuro Morishima(Ogaki Municipal Hospital), Kenji Andò(Kokura Memorial Hospital), Gaku Nakazawa(Kindai University), Satoru Suwa(Juntendo University Shizuoka Hospital), Itaru Hisauchi(Dokkyo Medical University Saitama Medical Center), Takashi Yamamoto(University of Tsukuba), Takeshi Morimoto(Hyogo Medical University), Ruka Yoshida(Japanese Red Cross Nagoya Daini Hospital), Manabu Ogita(Juntendo University Shizuoka Hospital), Masahiro Natsuaki(Saga University), Tetsuya Ishikawa(Saitama Prefecture), Ko Yamamoto(Kokura Memorial Hospital), Tomoya Kimura(Hyogo Medical University), Takenori Domei(Kokura Memorial Hospital), Hiroyuki Takenaka(Municipal Hirakata City Hospital), Koh Ono(Kyoto University)
European Heart Journal
August 31, 2024
Cited by 37


Related Papers